Quintiles-Led Registries User's Guide Published by AHRQ
Quintiles' Real-World & Late Phase Research division leads AHRQ effort for evaluating patient outcomes since 2005.
Quintiles-Led Registries User’s Guide Published by AHRQ
Quintiles announced that the U.S. Agency for Healthcare Research and Quality (AHRQ) has published the third edition of “Registries for Evaluating Patient Outcomes: A User’s Guide.” Quintiles’ Real-World & Late Phase Research division has led this effort to create the patient registries reference since 2005. This publication provides a comprehensive guide to the design, operation, analysis and evaluation of patient registries. Nancy A. Dreyer, MPH, Ph.D., senior editor of the handbook and global chief of Scientific Affairs at Quintiles served as a senior editor for the project. In addition, Dr. Dreyer and Dr. Priscilla Velentgas, senior director of Epidemiology at Quintiles, are also senior editors of a second AHRQ User’s Guide, titled “Developing a Protocol for Observational Comparative Effectiveness Research.”
The third edition of the registries user’s guide was created in collaboration with more than 240 individuals, representing industry, academia, government and patients. In total, there were 100 chapter contributors, 76 invited peer reviewers, plus public comment, and 109 case example contributors, with some individuals participating in multiple ways. The 11 new chapters address challenges related to design, operations, ethics, analysis, and legal and technical concerns, with topics including:
Click here for the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
